Arcutis biotherapeutics stock.

20 thg 10, 2023 ... Arcutis is selling 32,500,000 shares of common stock and, in lieu of common stock ... Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early ...Nov 27, 2023 · The stock of Arcutis Biotherapeutics Inc (ARQT) has seen a -2.21% decrease in the past week, with a -15.82% drop in the past month, and a -75.12% decrease in the past quarter. The volatility ratio for the week is 13.81%, and the volatility levels for the past 30 days are at 11.73% for ARQT. The […] Volume, 2.35M. Market Value, $179.33M. Shares Outstanding, 94.38M. EPS (TTM), -$4.9489. P/E Ratio (TTM), N/A. Dividend Yield, N/A. Latest Dividend, N/A.WESTLAKE VILLAGE - Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental new drug application (sNDA) for …The stock options have a ten-year term and an exercise price of $1.99 per share, equal to the per share closing price of Arcutis’ common stock as reported by Nasdaq on December 1, 2023.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with ...In addition, Arcutis has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of its common stock. The gross proceeds from the public offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Arcutis, are expected to be $100.0 million, excluding any exercise of ...Stock Quote & Chart. Change. Volume. Today's Open. Previous Close. Today's High. Today's Low. 52 Week High. 52 Week Low.

Nov 24, 2023 · A high-level overview of Arcutis Biotherapeutics, Inc. (ARQT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Apr 6, 2023 · Arcutis Biotherapeutics Inc’s Stock Price as of Market Close. As of April 06, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $12.03. Arcutis Biotherapeutics Inc is up 8.48% from its previous closing price of $11.09. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $10.67 and $11.23. Arcutis Biotherapeutics Inc is down 6.97% from its previous closing price of $7.82. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $7.82 and $8.26. Currently, there are 61.43 million shares of Arcutis Biotherapeutics Inc stock available for purchase. Unfortunately, Arcutis Biotherapeutics Inc’s P/E ratio ...Shares of Arcutis Biotherapeutics ( ARQT -3.16%) climbed 21.2% for the week after rising as high as 23.8%, according to data provided by S&P Global Market Intelligence. The medical dermatology ...May 9, 2023 · ARCUTIS BIOTHERAPEUTICS, INC. Condensed Balance Sheets (In thousands) March 31, December 31, 2023 2022 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 81,405 $ 53,641 Restricted cash 925 1,234 Trade receivable, net 12,769 8,458 Marketable securities 251,000 355,948 Inventories 8,551 WESTLAKE VILLAGE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical …

1 thg 2, 2021 ... Stock of Arcutis Biotherapeutics, a Westlake Village-based company developing dermatological treatments, shot up more than 30% on Feb.

According to the issued ratings of 9 analysts in the last year, the consensus rating for Arcutis Biotherapeutics stock is Moderate Buy based on the current 3 hold ratings and 6 buy ratings for ARQT. The average twelve-month price prediction for Arcutis Biotherapeutics is $33.78 with a high price target of $57.00 and a low price target of $6.00.

May 10, 2023 1:55 PM ET Arcutis Biotherapeutics, Inc. (ARQT) By: Jonathan Block, SA News Editor. CharlieAJA. Arcutis Biotherapeutics ( NASDAQ: ARQT) is down ~20% in Wednesday afternoon trading ...Arcutis Biotherapeutics' shares are down 15% year to date. Read more to see why ARQT stock is a buy for long-term investors. Arcutis Biotherapeutics' shares are down 15% year to date. Read more to ...Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, ACADIA Pharmaceuticals, and Alkermes. According to TipRanks , Ear has an average return of 13.4% and a 32.14% ...Nov 30, 2023 · Arcutis Announces Pricing of $100 Million Public Offering. WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage biopharmaceutical company focused on developing meaningf... 4 weeks ago - GlobeNewsWire. Track Arcutis Biotherapeutics Inc (ARQT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Arcutis Biotherapeutics price target lowered to $8 from $22 at Needham November 6, 2023TipRanks. Get Arcutis Biotherapeutics Inc (ARQT:NASDAQ) real-time stock quotes, news, price and financial ...Prescribing information. Arcutis Biotherapeutics, Inc; 2023. Dong C, Virtucio C, Zemska O, et al. Treatment of skin inflammation with benzoxaborole phosphodiesterase inhibitors: selectivity, cellular activity, and effect on cytokines associated with skin inflammation and skin architecture changes. J Pharmacol Exp Ther. 2016;358(3):413-422.Chris Shibutani, an analyst from Goldman Sachs, maintained the Hold rating on Arcutis Biotherapeutics (ARQT – Research Report). The associated price target is $6.00. Chris Shibutani has given ...According to the issued ratings of 9 analysts in the last year, the consensus rating for Arcutis Biotherapeutics stock is Moderate Buy based on the current 3 hold ratings and 6 buy ratings for ARQT. The average twelve-month price prediction for Arcutis Biotherapeutics is $33.78 with a high price target of $57.00 and a low price target of $6.00.Health Technology. Industry. Pharmaceuticals: Major. No executives to display. Corporate headquarters. --, --. Find real-time ARQT - Arcutis Biotherapeutics Inc stock quotes, company profile, news ...

The stock options vest over four years, with 25 percent vesting on the one-year anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Arcutis as of such vesting dates. The stock options have ...

Data delayed at least 15 minutes, as of Nov 30 2023 21:00 GMT. ... Use our equities screener to discover other potential opportunities. Find Similar Stocks ...5 thg 9, 2023 ... What Caused Arcutis Biotherapeutics Inc Stock's Price to Dip? Stock prices are primarily based on seller supply and buyer demand. But have you ...Track Arcutis Biotherapeutics Inc (ARQT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsMar 7, 2023 · As of March 07, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $13.69. Arcutis Biotherapeutics Inc is down 5.85% from its previous closing price of $14.54. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $14.43 and $15.47. Currently, there are 61.04 million shares of Arcutis ... Arcutis Biotherapeutics - ARQT - Stock Price Today - Zacks Arcutis Biotherapeutics (ARQT) (Real Time Quote from BATS) $1.99 USD +0.03 (1.53%) Updated Nov 28, 2023 10:40 AM ET Add to...Arcutis Biotherapeutics Inc (NASDAQ:ARQT) has a beta value of 0.76 and has seen 2.92 million shares traded in the last trading session. The company, currently valued at $187.82M, closed the last trade at $1.99 per share which meant it gained $0.15 on the day or 8.15% during that session. ... The ARQT stock price is -806.53% off its 52 …Nov 3, 2023 · Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with ...

Another classic case of short-interest stocks, Arcutis Biotherapeutics (NASDAQ:ARQT) on paper seems incredibly relevant. Leveraging advanced innovations in the field of dermatology, ...

Nov 29, 2023 · Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique ...

Arcutis Biotherapeutics Inc’s Stock Price as of Market Close. As of April 06, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $12.03. Arcutis Biotherapeutics Inc is up 8.48% from its previous closing price of $11.09. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $10.67 and $11.23.As of May 30, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $7.81. Arcutis Biotherapeutics Inc is down 7.02% from its previous closing price of $8.40. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $8.11 and $8.57. Currently, there are 61.17 million shares of Arcutis Biotherapeutics Inc ...Arcutis Biotherapeutics stock price forecast: $51; Market Cap: 179.32M, Enterprise value: 934.67M, P/E: -2.1, PEG ratio: 0.05, EPS: -4.43, Revenue: 49.04M, ...Arcutis Biotherapeutics Stock Performance. ARQT opened at $2.34 on Monday. Arcutis Biotherapeutics has a 52-week low of $2.13 and a 52-week high of $20.11. The firm has a market capitalization of ...Nov 2, 2023 · That’s why we’re here. Arcutis has a passion for doing and delivering better through innovation. But not just for the sake of innovating—innovation that delivers the results that matter most. The kind that simplifies complex disease management and solves the most persistent challenges of treating chronic inflammatory diseases of the skin. Dec 1, 2023 · Arcutis Biotherapeutics stock has received a consensus rating of buy. The average rating score is and is based on 30 buy ratings, 2 hold ratings, and 0 sell ratings. What was the 52-week low for ... Concurrent with the completion of the public offering, Arcutis sold to OrbiMed Advisors, LLC, an affiliate of one of the Company’s directors, 1,400,000 shares of its common stock in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, at a price per share equal to the public offering price.Sean Kim PhD, an analyst from JonesTrading, reiterated the Buy rating on Arcutis Biotherapeutics (ARQT – Research Report). The associated price target is $44.00. The associated price target is ...The replay of the webcast will be available on the Arcutis website following the call. About Arcutis . Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions.These 8 analysts have an average price target of $25.62 versus the current price of Arcutis Biotherapeutics at $2.49, implying upside. Below is a summary of how these 8 analysts rated Arcutis ...ARQT stock had a significant performance on November 3, 2023. According to data from CNN Money, eight analysts have offered 12-month price forecasts for Arcutis Biotherapeutics Inc, with a median target of $33.00. The high estimate for the stock price is $50.00, while the low estimate is $4.00.

Do the numbers hold clues to what lies ahead for the stock? Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of -0.77% and 20.54%, respectively, for the quarter ended ...Earnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($3.78) to ($2.65) per share. Arcutis Biotherapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 27th, 2024 based off prior year's report dates.WESTLAKE VILLAGE, Calif., May 09, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter ended March 31, 2023, and provided a business …Instagram:https://instagram. best private equity coursescomposer.tradepxys stocksolar edge tech stock Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 52,500 restricted stock units of Arcutis' common stock to eight newly hired employees. New ... pgim jennison utility cl avaluable 25 cent coins Arcutis Biotherapeutics last posted its earnings data on November 3rd, 2023. The reported ($0.73) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.90) by $0.17. The firm earned $38.11 million during the quarter, compared to the consensus estimate of $9.54 million. Arcutis Biotherapeutics has generated ($4. ...Arcutis Biotherapeutics Inc ARQT. Arcutis Biotherapeutics announced the pricing of a $100 million public offering of 32.5 million common shares at $2.50 per share. The company has a 52-week low of ... best gold sellers We would like to show you a description here but the site won’t allow us.In addition, Arcutis intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price. Morgan Stanley, Cowen, and Guggenheim Securities are acting as bookrunning managers for the proposed offering.